Health inequalities modular update to NICE health technology evaluations: the manual (PMG36) Methods / process manual consultation NICE process and methods 31 January 2025 Highly specialised ...

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Seven digital technologies to support self-management of chronic obstructive pulmonary disease (COPD) in adults can be used in the NHS during the evidence generation period. The technologies are: ...

All NICE products on people with learning disabilities. Includes any guidance and quality standards.

There is a simple discount patient access scheme for crizotinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Guidance that can help you make cost savings and find efficiencies in your local services. Includes impact reports and templates that allow you to accurately estimate savings for your local setting. A ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

The Innovation Scorecard reports on the use of medicines and medical technologies in the NHS in England which have been positively appraised by NICE.